2) the side reaction of radiotherapy

放疗毒副反应
3) Toxic and side effect

毒副反应
1.
Observation of the toxic and side effects after hyperthermal retention enema with arsenic trioxide in dogs;
目的 :观察家犬经三氧化二砷液高温保留灌肠后的毒副反应。
4) Adverse effect

毒副反应
1.
Methods:17 advanced retreated NSCLC patients received pemetrexed at a dose of 500 mg/m2, the chemotherapy was repeated every 21 days on two cycles until progressive disease or untolerant adverse effects.
本研究旨在观察培美曲塞单药治疗晚期复治的非小细胞肺癌的近期疗效及毒副反应。
5) side effect

毒副反应
1.
Objective: To reduce the side effects of chemotherapies and make the treatment go smoothly.
目的:减少或减轻恶性肿瘤患者化疗过程中的毒副反应,确保工作顺利进行。
2.
But because the drug used in chemotherapy somehow lacks selectivity, it has the side effect of damaging the normal cells of human body while it does suppress and kill the tumor cells.
采用抗癌药物毒性反应分度表、Karnofasky体力状况评分表为临床疗效评价指标,观察电针膈俞穴对癌症化疗毒副反应的减毒效应,治疗前后各评价一次。
3.
Conventional radiotherapy, however due to its technical restriction, the more volume of normal tissue, such as small intestine, rectum, bladder might be involved in radiation field, causing significant a serious of acute and chronic side effects.
方法:对2005年4月1日至2008年6月30日期间广西壮族自治区肿瘤医院妇瘤科收治的Ⅰb1-Ⅲb期宫颈癌患者48例进行回顾性研究,设立研究组为三维适形放疗组(23例),普通放疗组(25例)为对照组,分别比较研究组和对照组近期疗效、放疗毒副反应和生存率。
6) Toxic reaction

毒副反应
1.
Purpose:To observe the toxic reactions of all trans retinoic acid in the treatment of acute promyelocytic leukemia.
目的 :研究全反式维甲酸 (ATRA)治疗急性早幼粒细胞白血病 (APL)常见及少见毒副反应。
2.
Objective: The trial is to observe the effect and study the mechanism of "YANGWEIHEJI" on releasing toxic reactions of radiotherapy and chemotherapy and improving quality of life of tumor patients.
目的:本课题通过对经验方“养胃合剂”减轻放、化疗毒副反应进行临床研究,从主观的生存质量和客观的实验室指标观察其疗效,对其作用机制进行初步的分析,并探讨养胃合剂在临床上的适用范围。
补充资料:放射性碘标记的放射性药物
分子式:
CAS号:
性质: 131I是最早用于临床的放射性核素之一。临床上常用的碘标放射性药物有:(1)Nal31I,用于甲状腺显像和甲亢治疗;(2)心肌显像用131I(123I)-CO-长链脂肪酸;(3)脑功能显像用123I(131I)-IMP(N-异丙基对碘安非他命,N-isopropyl-p-iodoamphetamine),123I(131I)-HIPDM[N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine];(4)受体显像用123I(131I)标记变体配体,如D1,D2,乙酰胆碱,安定类受体显像剂;(5)用于放射免疫显像和治疗的131I标记抗肿病抗体;(6)肾上腺显像剂131I-6-碘胆固醇、131I-间-碘苄胍等。
CAS号:
性质: 131I是最早用于临床的放射性核素之一。临床上常用的碘标放射性药物有:(1)Nal31I,用于甲状腺显像和甲亢治疗;(2)心肌显像用131I(123I)-CO-长链脂肪酸;(3)脑功能显像用123I(131I)-IMP(N-异丙基对碘安非他命,N-isopropyl-p-iodoamphetamine),123I(131I)-HIPDM[N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine];(4)受体显像用123I(131I)标记变体配体,如D1,D2,乙酰胆碱,安定类受体显像剂;(5)用于放射免疫显像和治疗的131I标记抗肿病抗体;(6)肾上腺显像剂131I-6-碘胆固醇、131I-间-碘苄胍等。
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条